

Avacta Group PLC

14:08 18 Oct 2019

Avacta raises £9m as its moves towards first clinical trial

Biotech firm Avacta Group PLC (LON:AVCT) is to raise £9m to push ahead with a first clinical trial of anti-cancer treatment Pro-Doxorubicin.

Avacta will use the funds to accelerate the collaboration with Tufts University Medical School on the drug, which is a new form of standard cancer drug Doxorubicin.

WATCH: Avacta Group PLC boss sees a huge opportunity with new version of cancer treatment

Doxorubicin has been a standard of care for soft tissue sarcomas for 40 years, but its use is limited by the heart damage it causes. Even so, the drug still generates US\$1bn a year in revenues.

AVA6000, the combination with the technology licensed from Tufts last year is inert until activated by a tumour, which reduces the heart's exposure to the chemotherapy and concentrates the active drug in the tumour.

Testing of 'AVA6000 Pro-Doxorubicin' has been limited to mice so far, but Avacta plans to start dosing patients in a phase 1 clinical trial in the second quarter of 2020, pending application and regulatory approval.

Avacta had previously said its first drug into human trials would be an Affimer PD-L1 inhibitor cancer treatment known as AVA004, but has decided to focus on Pro-Doxorubicin because it provides an opportunity for major licensing deal much sooner.

The £9m of new money is being raised through a placing at 15p though there is also a small subscription.

Alastair Smith, chief executive, said that it was an "exciting time on all fronts" for the group and not just Pro-Doxorubicin.

Seven evaluations are ongoing with possible partners, he said, which includes four out of the top ten global diagnostics companies.

Heavier research spending meant a loss before tax of £11.1m, in the year to July.


Gross profits though jumped 72% to £3.2m, which included US\$2.5m received from new partner LG Chem Life Sciences.

Last December, LG Chem, a Korean group, agreed to fund development and eventually license Affimer technology in a deal potentially worth over US\$300m.

Price: 120.85

Market Cap: £300.92 m

1 Year Share Price Graph



Share Information

Code: AVCT

Listing: AIM

52 week High Low
215.36 12.6172

Sector: Pharma & Biotech

Website: www.avacta.com

Company Synopsis:

At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets. Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).